Gurney JG, Ness KK, Rosenthal J, et al. Visual, auditory, sensory, and motor impairments in long‐term survivors of hematopoietic stem cell transplantation performed in child‐hood: results from the Bone Marrow Transplant Survivor Study. Cancer. 2006; 106:1402–1408.39 39. Majhail NS, Ness KK, Burns LJ, et al. Late effects in survivors of Hodgkin and non‐Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Biol Blood Marrow Transplant. 2007; 13:1153–1159.
40 40. Brennan BM, Shalet SM. Endocrine late effects after bone marrow transplant. Br J Haematol. 2002; 118:58–66.
41 41. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplantation Survivor Study. Blood. 2007; 109:1765–1772.
42 42. Majhail NS, Challa TR, Mulrooney DA, et al. Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009; 15:1100–1107.
43 43. Ranke MB, Schwarze CP, Dopfer R, et al. Late effects after stem cell transplantation (SCT) in children – growth and hormones. Bone Marrow Transplant. 2005; 35(Suppl 1):S77–S81.
44 44. Sonis ST, Woods PD, White BA. Oral complications of cancer therapies. Pretreatment oral assessment. NCI Monogr. 1990;( 9):29–32.
45 45. Yao S, Smiley SL, West K, et al. Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16:1130–1137.
46 46. Campbell S, Sun CL, Kurian S, et al. Predictors of avascular necrosis of bone in long‐term survivors of hematopoietic cell transplantation. Cancer. 2009; 115:4127–4135.
47 47. Syrjala KL, Langer SL, Abrams JR, et al. Late effects of hematopoietic cell transplantation among 10‐year adult survivors compared with case‐matched controls. J Clin Oncol. 2005; 23:6596–6606.
48 48. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17:1072–1078.
49 49. Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. J Clin Oncol. 2011; 29:2397–2404.
50 50. Sostak P, Padovan CS, Eigenbrod S, et al. Cerebral angiitis in 4 patients with chronic GVHD. Bone Marrow Transplant. 2010; 45:1181–1188.
51 51. Saad AG, Alyea E, Wen P, et al. Graft‐versus‐host disease of the CNS after allogeneic bone marrow transplantation. J Clin Oncol. 2009; 27:e147–e149.
52 52. Rusiewicz A, DuHamel KN, Burkhalter J, et al. Psychological distress in long‐term survivors of hematopoietic stem cell transplantation. Psychooncology. 2008; 17:329–337.
53 53. Pereira DB, Christian LM, Patidar S, et al. Spiritual absence and 1‐year mortality after hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2010; 16(8):1171–1179.
54 54. Sun CL, Francisco L, Baker KS, et al. Adverse psychological outcomes in long‐term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). Blood. 2011; 118:4723–4731.
55 55. Wong FL, Francisco L, Togawa K, et al. Long‐term recovery after hematopoietic cell transplantation: predictors of quality‐of‐life concerns. Blood. 2010; 115:2508–2519.
56 56. Bishop MM, Beaumont JL, Hahn EA, et al. Late effects of cancer and hematopoietic stem‐cell transplantation on spouses or partners compared with survivors and survivor matched controls. J Clin Oncol. 2007; 25:1403–1411.
57 57. Armenian SH, Sun CL, Vase T, et al. Cardiovascular risk factors in hematopoietic cell transplantation (HCT) survivors: role in development of subsequent cardiovascular disease. Blood. 2012; 120(23):4505–4512.
58 58. Tichelli A, Passweg J, Wójcik D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008; 93:1203–1210.
59 59. Tichelli A, Rovo A, Passweg J, et al. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol. 2009; 2:583–601.
60 60. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009; 113:1175–1183.
61 61. Kolb HJ, Socie G, Duell T, et al. Malignant neoplasms in long‐term survivors of bone marrow transplantation (Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group). Ann Intern Med. 1999; 131:738–744.
62 62. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996; 87:3633–3639.
63 63. Gallagher G, Forrest DL. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer. 2007; 109:84–92.
64 64. Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012; 62(2):118–128.
65 65. Cohen A, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem‐cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol. 2007; 25:2449–2454.
66 66. Leisenring W, Friedman DL, Flowers ME, et al. Non‐melanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol. 2006; 24:1119–1126.
67 67. Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT‐Late Effect Working Party. Blood. 2008; 111:939–944.
68 68. Nakamizo A, Akagi Y, Amano T, et al. Donor‐derived adult T‐cell leukaemia. Lancet. 2011; 377:1124.
69 69. Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant. 2011; 17:771–789.
70 70. Krenauer A, Moll A, Pönisch W, et al. EBV‐associated post‐transplantation B‐cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression – a case report. Diagn Pathol. 2010; 5:21.
71 71. Snyder MJ, Stenzel TT, Buckley PJ, et al. Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation. Am J Surg Pathol. 2004; 28(6):794–800.
72 72. Gandelman JS, Byrne MT, Mistry AM, et al. Machine learning reveals chronic graft‐versus‐host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. Haematologica. 2019; 104(1):189–96.
73 73. Wang X, Sun CL, Quinones‐Lombrana A, et al. CELF4 variant and anthracycline‐related cardiomyopathy: a children’s oncology group genome‐wide association study. J Clin Oncol. 2016; 34(8):863.
74 74. Peled JU, Gomes AL, Devlin SM, et al. Microbiota as predictor of mortality in allogeneic hematopoietic‐cell transplantation. N Engl J Med. 2020; 382(9):822–834.
75 75.
